Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 13, 2026Frontiers in ImmunologyOpen Access

Prognostic utility of circulating tumor DNA assessment in immune checkpoint inhibitor-treated advanced non-small cell lung cancer: a systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

YWYulin WangSWShuang WuYWY L Wei

Discussion

Loading...

Member takes

Overview

Meta-analysis assesses circulating tumor DNA as a prognostic indicator for survival in advanced NSCLC patients receiving immune checkpoint inhibitors, suggesting personalized treatment strategies.

Key Points

  • The analysis aims to evaluate the prognostic significance of circulating tumor DNA (ctDNA) in predicting survival outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs).
  • Systematic review of 31 studies with 2,107 patients from multiple databases.
  • Cochrane RoB-2 and Newcastle-Ottawa Scale used to assess study quality.
  • Hazard ratios and 95% confidence intervals pooled using random/fixed-effects models.
  • Patients with undetectable ctDNA at baseline had prolonged PFS (HR = 0.49, 95% CI: 0.34–0.70, P < 0.01) and OS (HR = 0.45, 95% CI: 0.32–0.65, P < 0.01).
  • ctDNA reduction during treatment significantly improved PFS (HR = 0.27, 95% CI: 0.21–0.35, P < 0.01) and OS (HR = 0.23, 95% CI: 0.17–0.31, P < 0.01).
  • Complete molecular response showed the strongest predictive power for PFS (HR = 0.27, 95% CI: 0.18–0.41, P < 0.01) and OS (HR = 0.19, 95% CI: 0.12–0.29, P < 0.01).

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf2a9faef96ed7f0556fchttps://doi.org/10.3389/fimmu.2026.1812209
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1Liquid biopsy: current technology and clinical applications2022 · 940 citations